Full Press Release Details
Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth.
IMTX
Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth
Key Takeaway: Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+20%
120-day peak, hindsight
Typical move
3.9%
average across 7 past catalysts
Lead asset
IMA401
Phase 1 · Refractory Cancer